Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Nov 28;10(12):3053.
doi: 10.3390/biomedicines10123053.

Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis

Michal Tomcik  1
Affiliations
Editorial

Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis

Michal Tomcik. Biomedicines. .

Abstract

Systemic sclerosis (scleroderma, SSc) is one of the most challenging rheumatic diseases, characterized by vasculopathy, dysregulation of the immune response, and progressive tissue fibrosis affecting the skin, lungs, heart, digestive tract, and kidneys [...].

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Similar articles

See all similar articles

References

    1. Denton C.P., Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–1699. doi: 10.1016/S0140-6736(17)30933-9. - DOI - PubMed
    1. Papadimitriou T.I., van Caam A., van der Kraan P.M., Thurlings R.M. Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis. Biomedicines. 2022;10:316. doi: 10.3390/biomedicines10020316. - DOI - PMC - PubMed
    1. Cardoneanu A., Burlui A.M., Macovei L.A., Bratoiu I., Richter P., Rezus E. Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6? Biomedicines. 2022;10:318. doi: 10.3390/biomedicines10020318. - DOI - PMC - PubMed
    1. Szabo I., Muntean L., Crisan T., Rednic V., Sirbe C., Rednic S. Novel Concepts in Systemic Sclerosis Pathogenesis: Role for miRNAs. Biomedicines. 2021;9:1471. doi: 10.3390/biomedicines9101471. - DOI - PMC - PubMed
    1. Zaaroor Levy M., Rabinowicz N., Yamila Kohon M., Shalom A., Berl A., Hornik-Lurie T., Drucker L., Tartakover Matalon S., Levy Y. MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors. Biomedicines. 2022;10:629. doi: 10.3390/biomedicines10030629. - DOI - PMC - PubMed

Publication types

LinkOut - more resources